This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Levofloxacin Pharmacokinetics (PK) in the Severely Obese

This study has been completed.
Ortho-McNeil Pharmaceutical
Information provided by (Responsible Party):
Scott Morehead, University of Kentucky Identifier:
First received: September 12, 2005
Last updated: September 12, 2012
Last verified: September 2012

Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations.

The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.

Condition Intervention Phase
Obesity Critical Illness Drug: Levofloxacin 750 mg IV Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Levofloxacin Pharmacokinetics in the Severely Obese

Resource links provided by NLM:

Further study details as provided by Scott Morehead, University of Kentucky:

Primary Outcome Measures:
  • Area Under the Curve [ Time Frame: 24 hours ]
    The objective of this study is to determine if therapeutic concentrations are likely after giving a standard dose of levofloxacin to critically ill obese individuals

Enrollment: 15
Study Start Date: January 2005
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Levofloxacin
Patients receiving levofloxacin 750mg IV
Drug: Levofloxacin 750 mg IV
PK in obesity
Other Name: Levaquin

  Show Detailed Description


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. 18 to 55 years of age
  2. Body mass index > 35 kg/m2
  3. Has been prescribed levofloxacin, but the medication has not yet been administered (hospitalized cohort only)

Exclusion Criteria:

  1. Hypersensitivity to fluoroquinolones
  2. Creatinine clearance < 50 ml/min
  3. Administration of levofloxacin within the previous 7 days
  4. Pregnant or lactating females
  5. Participation in another investigational protocol within the past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00176306

United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
Sponsors and Collaborators
University of Kentucky
Ortho-McNeil Pharmaceutical
Principal Investigator: Richard S Morehead, MD University of Kentucky
  More Information

Responsible Party: Scott Morehead, MD, University of Kentucky Identifier: NCT00176306     History of Changes
Other Study ID Numbers: CAPSS-391
CAPSS-391 ( Other Identifier: Johnson & Johnson )
Study First Received: September 12, 2005
Results First Received: August 2, 2011
Last Updated: September 12, 2012

Additional relevant MeSH terms:
Critical Illness
Disease Attributes
Pathologic Processes
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Anti-Bacterial Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on September 21, 2017